VNDA. PR. new uptrend. $4.12

Stock Maven. 33% - 80% buy.

1/23/13 Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder

-- Tasimelteon significantly maintains entrainment of circadian rhythms
-- Discontinuation of tasimelteon results in significant clinical deterioration

stockcharts.com